ESO-101 Sales Forecast Summary

Key Factors Driving ESO-101 Growth

Positive Phase II Clinical Data Validating Efficacy

• ESO-101 has demonstrated statistically significant histologic improvement in patients with eosinophilic esophagitis (EoE) in a randomized, placebo-controlled Phase II trial (the ACESO study). It significantly reduced peak eosinophil counts compared to placebo, with nearly half of treated patients achieving histologic remission (< 15 eosinophils per high-power field).
• The Phase II results also showed significant reductions in endoscopic damage scores (EREFS) and clinical symptoms, supporting ESO-101’s potential disease-modifying effects and mechanistic validity.
• Crucially, these outcomes were achieved with a favorable safety and tolerability profile, with no cases of candidiasis — a known risk of corticosteroid therapies for EoE — highlighting a strong safety advantage.

Differentiated Localized Delivery Mechanism

• ESO-101 employs a novel esophagus-targeted drug delivery system that uses a mucoadhesive film carrying mometasone furoate. Upon swallowing, the film unrolls and adheres to the esophageal mucosa, increasing local contact time and maximizing drug deposition in the target tissue.
• This innovative platform is designed to overcome the ultra-short contact time (approximately 45 seconds) seen with traditional oral formulations, potentially offering improved efficacy and reduced systemic exposure compared with standard swallowed steroids.

Orphan Drug Designation Supporting Development Incentives

• ESO-101 has received Orphan Drug Designation from the US Food and Drug Administration for EoE, which provides regulatory and commercial incentives such as reduced fees, tax credits, and potential market exclusivity upon approval.

Large and Growing EoE Market Opportunity

• In 2023, about 800,000 prevalent EoE cases were estimated across the 7 major markets (7MM), and this is expected to grow at a sustained rate through 2034.
• Market research sources estimate the global eosinophilic esophagitis treatment market could expand from roughly USD 1.8 billion in 2023 toward significantly higher valuations by 2034, driven by the launch of targeted therapies and wider adoption.
• Emerging specialized treatments like ESO-101, alongside drugs such as DUPIXENT and new oral formulations, are expected to reshape the competitive landscape in the coming decade.

Strategic Positioning Against Competing Therapies

• The current EoE landscape includes approved biologics (e.g., dupilumab) and other investigational localized therapies (e.g., APT-1011), as well as formulations like budesonide oral suspension.
• ESO-101’s targeted delivery approach and safety profile position it as a potentially more convenient, highly localized alternative to existing drugs, which may help it differentiate clinically and commercially once approved.

ESO-101 Recent Developments

In December 2024, EsoCap AG, the Swiss biotech company dedicated to improving the lives of patients with serious diseases of the upper gastrointestinal tract, announced that the complete results of the ACESO Phase II study evaluating ESO-101 for the treatment of eosinophilic esophagitis have been published in Alimentary Pharmacology & Therapeutics. The data demonstrate that ESO-101 was safe and well tolerated and improved both histologic and endoscopic outcomes in adults with active eosinophilic esophagitis (EoE). EoE is a chronic, local, immune-mediated esophageal disease characterized clinically by symptoms associated with esophageal dysfunction, including dysphagia (i.e., swallowing difficulties), food impaction, heartburn and vomiting, and histologically by eosinophil-dominated inflammation. 

“ESO-101 Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of ESO-101 for potential indication like Eosinophilic oesophagitis in the 7MM. A detailed picture of ESO-101’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the ESO-101 for potential indications. The ESO-101 market report provides insights about ESO-101’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current ESO-101 performance, future market assessments inclusive of the ESO-101 market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of ESO-101 sales forecasts, along with factors driving its market.

ESO-101 Drug Summary

ESO-101 is a novel, investigational esophagus-targeted drug delivery system developed by EsoCap AG using their proprietary EsoCap platform, consisting of a swallowable capsule containing a rolled-up thin mucoadhesive film loaded with mometasone furoate, a potent topical corticosteroid, designed to unroll and adhere directly to the esophageal mucosa for up to 15 minutes of prolonged contact time, enabling localized anti-inflammatory action with minimal systemic exposure. Primarily indicated for adults with active eosinophilic esophagitis (EoE), a chronic immune-mediated esophageal disease causing dysphagia, food impaction, and eosinophil-predominant inflammation, it demonstrated statistically significant histologic efficacy in the Phase II ACESO trial (randomized, double-blind, placebo-controlled; n=43), achieving a 50% reduction in peak esophageal eosinophil counts (p<0.05) versus no change with placebo, alongside endoscopic improvements (EREFS score reductions), dysphagia symptom relief trends, high patient compliance (100%), and a favorable safety profile with low mild-to-moderate adverse events (7.1% vs. 26.7% placebo) and no esophageal candidiasis or serious drug-related issues. Granted FDA Orphan Drug Designation for EoE, ESO-101 leverages the user-friendly delivery device (swallowed via a drinking cup holder) to overcome limitations of standard topical steroids like short transit time; as of early 2026, it remains in clinical development post-positive Phase II topline and publication results, with no approvals yet. The report provides ESO-101’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the ESO-101 Market Report 

The report provides insights into:

• A comprehensive product overview including the ESO-101 MoA, description, dosage and administration, research and development activities in potential indication like Eosinophilic oesophagitis.
• Elaborated details on ESO-101 regulatory milestones and other development activities have been provided in ESO-101 market report.
• The report also highlights ESO-101‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan. 
• The ESO-101 market report also covers the patents information, generic entry and impact on cost cut.
• The ESO-101 market report contains current and forecasted ESO-101 sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The ESO-101 market report also features the SWOT analysis with analyst views for ESO-101 in potential indications.

Methodology

The ESO-101 market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

ESO-101 Analytical Perspective by DelveInsight

• In-depth ESO-101 Market Assessment

This ESO-101 sales market forecast report provides a detailed market assessment of ESO-101 for potential indication like Eosinophilic oesophagitis in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted ESO-101 sales data uptil 2034.

• ESO-101 Clinical Assessment

The ESO-101 market report provides the clinical trials information of ESO-101 for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

ESO-101 Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

ESO-101 Market Potential & Revenue Forecast

• Projected market size for the ESO-101 and its key indications
• Estimated ESO-101 sales potential (ESO-101 peak sales forecasts)
• ESO-101 Pricing strategies and reimbursement landscape

ESO-101 Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• ESO-101 Market positioning compared to existing treatments
• ESO-101 Strengths & weaknesses relative to competitors

ESO-101 Regulatory & Commercial Milestones

• ESO-101 Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

ESO-101 Clinical Differentiation

• ESO-101 Efficacy & safety advantages over existing drugs
• ESO-101 Unique selling points 

ESO-101 Market Report Highlights 

• In the coming years, the ESO-101 market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The ESO-101 companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ESO-101’s dominance.
• Other emerging products for corneal disorders are expected to give tough market competition to ESO-101 and launch of late-stage emerging therapies in the near future will significantly impact the market. 
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ESO-101 in potential indications.
• Analyse ESO-101 cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted ESO-101 sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of ESO-101 in potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of ESO-101? How strong is ESO-101’s clinical and commercial performance?
• What is ESO-101’s clinical trial status in each individual indications such as Eosinophilic oesophagitis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ESO-101 Manufacturers?
• What are the key designations that have been granted to ESO-101 for potential indications? How are they going to impact ESO-101’s penetration in various geographies?
• What is the current and forecasted ESO-101 market scenario for potential indications? What are the key assumptions behind the forecast? 
• What are the current and forecasted sales of ESO-101 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?  
• What are the other emerging products available and how are these giving competition to ESO-101 for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is ESO-101? What is the duration of therapy and what are the geographical variations in cost per patient?